{
  "id": "mhgap#risk_safety_c8860903",
  "content": "medicine or stopping the medicine gradually and\ny The majority of studies were conducted in offering alternative interventions.\nHICs. Further research is needed to enhance y For adults under 30 years of age who are\nunderstanding on use in low-resource settings. prescribed antidepressants:\ny Limited evidence on outcomes such as functioning. – Inform them of increased risk of suicidal thinking\ny Few studies directly compared psychological and self-harm behaviour among younger people\ninterventions with pharmacological interventions, when taking these medicines.\nparticularly for adults with GAD, including for – Ensure follow-up within one week after initiating\nimportant outcomes like symptom reduction, the medicines if at all possible.\nadverse effects, acceptability, sustained response\n– Monitor and follow-up on suicidal thinking and\nand functioning.\nself-harm on regular (e.g. weekly) basis within\nthe first month after initiating the medicine or\nImplementation considerations\nchanging the dose.\ny Providers should keep in mind the possible adverse\ny If the medicine is effective, continue use for at least\neffects associated with antidepressant medicines,\nsix months after remission to reduce likelihood\ntreatment availability and individual preferences.\nof relapse.\nDiscontinuities in drug availability (common in\n19",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety medicine or stopping the medicine gradually and\ny The majority of studies were conducted in offering alternative interventions.\nHICs. Further research is needed to enhance y For adults under 30 years of age who are\nunderstanding on use in low-resource settings. prescribed antidepressants:\ny Limited evidence on outcomes such as functioning. – Inform them of increased risk of suicidal thinking\ny Few studies directly compared psychological and self-harm behaviour among younger people\ninterventions with pharmacological interventions, when taking these medicines.\nparticularly for adults with GAD, including for – Ensure follow-up within one week after initiating\nimportant outcomes like symptom reduction, the medicines if at all possible.\nadverse effects, acceptability, sustained response\n– Monitor and follow-up on suicidal thinking and\nand functioning.\nself-harm on regular (e.g. weekly) basis within\nthe first month after initiating the medicine or\nImplementation considerations\nchanging the dose.\ny Providers should keep in mind the possible adverse\ny If the medicine is effective, continue use for at least\neffects associated with antidepressant medicines,\nsix months after remission to reduce likelihood\ntreatment availability and individual preferences.\nof relapse.\nDiscontinuities in drug availability (common in\n19 Medicine or stopping the medicine gradually and\ny the majority of studies were conducted in offering alternative interventions. hics."
}